Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy-Reference-Cited by-同舟云学术

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy

Published:2019-05-01 Issue:5 Volume:5 Page:623
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Oudard Stéphane¹,Latorzeff Igor²,Caty Armelle³,Miglianico Laurent⁴,Sevin Emmanuel⁵,Hardy-Bessard Anne Claire⁶,Delva Remy⁷,Rolland Frédéric⁸,Mouret Loic⁹,Priou Franck¹⁰,Beuzeboc Philippe¹¹,Gravis Gwenaelle¹²,Linassier Claude¹³,Gomez Philippe¹⁴,Voog Eric¹⁵,Muracciole Xavier¹⁶,Abraham Christine¹⁷,Banu Eugeniu¹⁸,Ferrero Jean-Marc¹⁹,Ravaud Alain²⁰,Krakowski Ivan²¹,Lagrange Jean-Léon²²,Deplanque Gaël²³,Zylberait David²⁴,Bozec Laurence²⁵,Houede Nadine²⁶,Culine Stéphane²⁷,Elaidi Reza²⁸

Affiliation:

1. Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France

2. Department of Oncology Radiotherapy, Clinique Pasteur, Toulouse, France

3. Department of Medical Oncology, Centre Galilée, Hôpital Privé la Louvière, Lille, France

4. Department of Oncology Radiotherapy, Centre Hospitalier Privé St Grégoire, Rennes, France

5. Department of Medical Oncology, Centre François Baclesse, Caen, France

6. Department of Medical Oncology, Hôpital Privé des Côtes d'Armor, Plérin, France

7. Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France

8. Department of Medical Oncology, Institut de Cancérologie de l'Ouest, St Herblain, France

9. Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

10. Department of Medical Oncology, Centre Hospitalier de Vendée, La Roche sur Yon, France

11. Department of Medical Oncology, Institut Curie, Paris, France

12. Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

13. Department of Medical Oncology, Centre Hospitalier Bretonneau, Tours, France

14. Department of Oncology Radiotherapy, Centre Joliot Curie, Rouen, France

15. Department of Medical Oncology, Clinique Victor Hugo, Institut Inter-régional de Cancérologie, Le Mans, France

16. Department of Oncology Radiotherapy, Hôpital de la Timone, Marseille, France

17. Department of Medical Oncology, Centre Hospitalier Versailles André Mignot, Le Chesnay, France

18. Department of Medical Oncology, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania

19. Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France

20. Department of Medical Oncology, Hôpital St Andre, Bordeaux, France

21. Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre Les Nancy, France

22. Department of Medical Oncology, Hôpital Henri Mondor, Creteil, France

23. Department of Medical Oncology, Fondation Hopital St Joseph, Paris, France

24. Department of Medical Oncology, Centre Hospitalier de Compiegne, Compiegne, France

25. Department of Medical Oncology, Hôpital Foch, Suresnes, France

26. Department of Medical Oncology, Institut Bergonie, Bordeaux, France

27. Department of Medical Oncology, Hôpital St Louis, Paris, France

28. Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie, Paris, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/5/623/17575115/jamaoncology_oudard_2019_oi_180114.pdf

Reference39 articles.

1. Natural history of progression after PSA elevation following radical prostatectomy.;Pound;JAMA,1999

2. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.;Ward;J Urol,2003

3. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.;Antonarakis;BJU Int,2012

4. Validation of increasing prostate specific antigen as a predictor of PC death after treatment of localized PC with surgery or radiation.;Albertsen;J Urol,2004

5. How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure.;Jhaveri;Semin Urol Oncol,1999

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-13

2. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy;Journal of Urology;2024-04

3. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA;JCO Clinical Cancer Informatics;2024-03

4. Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer;Cancer Treatment Reviews;2024-01

5. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer;Annals of Oncology;2023-07